Intellia Therapeutics (NTLA) Cash from Financing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Financing Activities data on file, last reported at $33.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $33.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $165.1 million (up 31.25% YoY), and the FY2025 annual result was $131.5 million, down 29.21% from the prior year.
• Cash from Financing Activities improved to $33.6 million in Q1 2026 per NTLA's latest filing, from $2.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $505.8 million in Q4 2022 and troughed at $2.0 million in Q4 2025.
• A 5-year average of $66.5 million and a median of $28.8 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities surged 22082.59% in 2022, then slumped 97.82% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $505.8 million in 2022, then tumbled by 78.95% to $106.5 million in 2023, then tumbled by 97.82% to $2.3 million in 2024, then declined by 14.67% to $2.0 million in 2025, then soared by 1597.98% to $33.6 million in 2026.
• Business Quant data shows NTLA's Cash from Financing Activities at $33.6 million in Q1 2026, $2.0 million in Q4 2025, and $114.9 million in Q3 2025.